Taken together, our results indicate that EMPA administration activates the AKT/eNOS/NO pathway and contributes to the suppression of catecholamine-induced apoptosis in ECs and the enhancement of capillarization in heart, leading to improvement of cardiac dysfunction in our TAC model (Fig. 6H). The gene discussed is AKT1; the disease is persistent truncus arteriosus.